Table 3 Incidence of renal function deterioration and adjusted hazard ratio for renal function deterioration by baseline CKD stage using allopurinol as reference
Person-days of follow-up | Number of patients | Events of CKD progression | Incidence rate (95% CI) per 1000 person-days | Hazard ratio (95% CI) | |
|---|---|---|---|---|---|
Entire cohort | 434,716 | 5860 | 741 | 1.70 (1.58–1.83) | – |
Type of ULD | |||||
Allopurinol | 19,680 | 532 | 39 | 1.98 (1.36–2.60) | Reference |
Febuxostat | 83,022 | 1105 | 156 | 1.88 (1.58–2.17) | 1.14 (0.80–1.66) |
Uricosuric agents | 332,014 | 4223 | 546 | 1.64 (1.51–1.78) | 0.92 (0.67–1.31) |
eGFR ≥ 90 | |||||
Allopurinol | 4031 | 113 | 11 | 2.73 (1.12–4.34) | Reference |
Febuxostat | 5861 | 85 | 27 | 4.61 (2.87–6.34) | 1.99 (0.99–4.28) |
Uricosuric agents | 97,969 | 1131 | 208 | 2.12 (1.83–2.41) | 0.91 (0.51–1.82) |
eGFR 60–89 | |||||
Allopurinol | 6134 | 163 | 12 | 1.96 (0.85–3.06) | Reference |
Febuxostat | 9141 | 147 | 25 | 2.73 (1.66–3.81) | 1.43 (0.72–2.99) |
Uricosuric agents | 123,774 | 1626 | 225 | 1.82 (1.58–2.06) | 1.12 (0.64–2.14) |
eGFR 30–59 | |||||
Allopurinol | 7873 | 204 | 14 | 1.78 (0.85–2.71) | Reference |
Febuxostat | 44,744 | 557 | 76 | 1.70 (1.32–2.08) | 0.97 (0.55–1.84) |
Uricosuric agents | 95,166 | 1257 | 97 | 1.02 (0.82–1.22) | 0.93 (0.53–1.75) |
eGFR 15–29 | |||||
Allopurinol | 1642 | 52 | 2 | 1.22 (0.15–4.40) | Reference |
Febuxostat | 23,276 | 316 | 28 | 1.20 (0.76–1.65) | 1.40 (0.33–10.15) |
Uricosuric agents | 15,105 | 209 | 16 | 1.06 (0.54–1.58) | 1.28 (0.30–9.34) |